Boehringer Ingelheim: all 2,305 studies
Page 16 of 24. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy SubjectsCompletedNCT02256826Phase 1
- Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male VolunteersCompletedNCT02256813Phase 1
- Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without FoodCompletedNCT02256787Phase 1
- Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy SubjectsCompletedNCT02256774Phase 1
- Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male VolunteersCompletedNCT02256761Phase 1
- Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male VolunteersCompletedNCT02256748Phase 1
- Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female VolunteersCompletedNCT02256735Phase 1
- In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male SubjectsCompletedNCT02256722Phase 1
- Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female VolunteersCompletedNCT02256709Phase 1
- Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male VolunteersCompletedNCT02254720Phase 1
- Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02254707Phase 1/2
- A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male VolunteersCompletedNCT02254538Phase 1
- Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male VolunteersCompletedNCT02254226Phase 1
- Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male VolunteersCompletedNCT02254187Phase 1
- Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male VolunteersCompletedNCT02254174Phase 1
- Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female VolunteersTerminatedNCT02254161Phase 1
- The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)CompletedNCT02254148Phase 1
- Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male VolunteersCompletedNCT02254135Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male VolunteersCompletedNCT02254122Phase 1
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male VolunteersCompletedNCT02254109Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human SubjectsCompletedNCT02254096Phase 1
- Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male SubjectsCompletedNCT02254083Phase 1
- Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal ImpairmentCompletedNCT02254070Phase 1
- Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male SubjectsCompletedNCT02254057Phase 1
- Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or EsophagusTerminatedNCT02254044Phase 1
- Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast CancerTerminatedNCT02254031Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT02254018Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast CancerCompletedNCT02254005Phase 1
- Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male VolunteersCompletedNCT02253953Phase 1
- Pharmacokinetics and Safety of BILR 355 in Healthy Male VolunteersCompletedNCT02253940Phase 1
- Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy VolunteersCompletedNCT02253927Phase 1
- Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male VolunteersCompletedNCT02253914Phase 1
- Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy VolunteersCompletedNCT02253901Phase 1
- Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT02253888Phase 1
- Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult VolunteersCompletedNCT02253875Phase 1
- Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male VolunteersCompletedNCT02253862Phase 1
- Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult VolunteersCompletedNCT02253849Phase 1
- Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of RitonavirCompletedNCT02253836Phase 1
- Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult VolunteersCompletedNCT02253823Phase 1
- Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male SubjectsCompletedNCT02253797Phase 1
- Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy VolunteersCompletedNCT02251873Phase 1
- Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsCompletedNCT02251795Phase 1
- Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of TipranavirCompletedNCT02251769Phase 1
- Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected SubjectsCompletedNCT02251223Phase 1/2
- Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid ArthritisCompletedNCT02251210Phase 2
- Safety and Tolerability of BIII 890 in Patients With Acute Ischemic StrokeCompletedNCT02251197Phase 2
- Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pHCompletedNCT02251184Phase 4
- Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult VolunteersCompletedNCT02251171Phase 1
- Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsCompletedNCT02251158Phase 1
- Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy VolunteersCompletedNCT02251145Phase 1
- Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy VolunteersCompletedNCT02251132Phase 1
- The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy VolunteersCompletedNCT02251119Phase 1
- Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedNCT02249442Phase 1
- Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy VolunteersCompletedNCT02249416Phase 1
- Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer TypeCompletedNCT02249403Phase 2
- Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer TypeTerminatedNCT02249351Phase 2
- Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02249338Phase 2
- The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial AsthmaCompletedNCT02249312Phase 2
- Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02249247Phase 2
- Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without TipranavirCompletedNCT02249130Phase 2
- Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male VolunteersCompletedNCT02249117Phase 1
- Antihypertensive Medications and the Risk of SepsisCompletedNCT02248896
- Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02248883Phase 1
- Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's DiseaseCompletedNCT02248220
- Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's DiseaseCompletedNCT02248207
- Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02248181
- Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02248168
- Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)CompletedNCT02248155
- Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)CompletedNCT02248142
- Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and HydrochlorothiazideCompletedNCT02248129
- Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer TypeTerminatedNCT02248116Phase 2/3
- Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)CompletedNCT02247375Phase 1
- Observational Study of Tamsulosin in Patients With Benign Prostatic HyperplasiaCompletedNCT02245555
- The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)CompletedNCT02245542
- Safety Profile of Secotex ® in Patients With Benign Prostatic HyperplasiaCompletedNCT02245529
- Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)CompletedNCT02245503
- Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary SymptomsCompletedNCT02245490Phase 4
- Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential HypertensionCompletedNCT02245464
- Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy VolunteersCompletedNCT02245451Phase 1
- Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult VolunteersTerminatedNCT02245438Phase 1
- Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT02245269Phase 1
- Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)CompletedNCT02244346
- Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)CompletedNCT02244333
- Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)CompletedNCT02244320
- Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic BlockadeCompletedNCT02244307
- FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)CompletedNCT02244294Phase 2
- Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding SymptomsCompletedNCT02244281Phase 2
- Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic HyperplasiaCompletedNCT02244268
- FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic HyperplasiaCompletedNCT02244255Phase 4
- Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic HyperplasiaCompletedNCT02244242Phase 4
- Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) PatientsCompletedNCT02244229Phase 4
- Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02244216
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male VolunteersCompletedNCT02244203Phase 1
- Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy VolunteersCompletedNCT02244190Phase 1
- Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)CompletedNCT02243566
- Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy VolunteersCompletedNCT02243553Phase 1
- TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or OlderCompletedNCT02242877
- Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood PressureCompletedNCT02242864
- Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and PatientsCompletedNCT02242851
- Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionCompletedNCT02242838